Department of Hematology, General Hospital of Central Theater Command, Wuhan, Hubei Province, People's Republic of China.
Oncology Department, General Hospital of Central Theater Command, Wuhan, Hubei Province, People's Republic of China.
Hematology. 2024 Dec;29(1):2399419. doi: 10.1080/16078454.2024.2399419. Epub 2024 Sep 13.
Circular RNA_0003489 (Circ_0003489) promotes multiple myeloma (MM) progression and bortezomib resistance in MM cells, while its potential as a biomarker in newly diagnosed MM (NDMM) patients is unclear. Thus, this study aimed to investigate the association of circ_0003489 expression with treatment response and survival in NDMM patients who received bortezomib-based induction therapy.
Bone marrow (BM) specimens from 85 NDMM patients at diagnosis or before treatment and from 15 donor controls during BM examination were retrieved in this retrospective study. Circ_0003489 derived from BM plasma cells was detected by reverse transcription-quantitative polymerase chain reaction and cut by quartile and median for further analysis.
Circ_0003489 expression was increased in NDMM patients versus donor controls (< 0.001). Circ_0003489 quartile was positively correlated with BM plasma cells (= 0.040), international staging system (ISS) stage (= 0.007), the revision of ISS stage (= 0.003), beta-2-microglobulin (= 0.011), and lactate dehydrogenase (= 0.042) in NDMM patients. Increased circ_0003489 quartile was linked with a lower possibility of achieving complete response (= 0.020) and partial response or better (= 0.041) in NDMM patients. Elevated circ_0003489 expression cut by quartile (= 0.020) and cut by median (= 0.006) were linked with decreased progression-free survival (PFS) in NDMM patients. Increased circ_0003489 expression cut by median was associated with shortened overall survival (OS) in NDMM patients (= 0.038). Meanwhile, higher circ_0003489 quartile independently forecasted poorer PFS (hazard ratio = 1.342, = 0.045), but not OS in NDMM patients.
Circ_0003489 expression is increased and reflects unfavorable treatment response and survival in NDMM patients who receive bortezomib-based induction therapy.
环状 RNA_0003489（Circ_0003489）可促进多发性骨髓瘤（MM）的进展和硼替佐米耐药，但其在新诊断的 MM（NDMM）患者中的作为生物标志物的潜力尚不清楚。因此，本研究旨在探讨 Circ_0003489 表达与接受硼替佐米为基础的诱导治疗的 NDMM 患者治疗反应和生存的关系。
在这项回顾性研究中，从 85 名 NDMM 患者的诊断或治疗前骨髓（BM）标本和 15 名供体对照者的 BM 检查中提取 BM 浆细胞中的 Circ_0003489，采用逆转录定量聚合酶链反应检测，按四分位数和中位数进行切割进行进一步分析。
与供体对照者相比，NDMM 患者的 Circ_0003489 表达增加（<0.001）。Circ_0003489 四分位数与 BM 浆细胞呈正相关（=0.040）、国际分期系统（ISS）分期（=0.007）、ISS 分期修订（=0.003）、β-2-微球蛋白（=0.011）和乳酸脱氢酶（=0.042）。Circ_0003489 四分位数升高与 NDMM 患者完全缓解（=0.020）和部分缓解或更好（=0.041）的可能性降低有关。Circ_0003489 四分位数升高（=0.020）和中位数升高（=0.006）与 NDMM 患者无进展生存期（PFS）降低有关。Circ_0003489 表达中位数升高与 NDMM 患者总生存期（OS）缩短有关（=0.038）。同时，较高的 Circ_0003489 四分位数独立预测了 NDMM 患者 PFS 较差（危险比=1.342，=0.045），但 OS 较差。
Circ_0003489 表达增加，反映了接受硼替佐米为基础的诱导治疗的 NDMM 患者治疗反应和生存不良。
